Title:
抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ
Document Type and Number:
Japanese Patent JP6674543
Kind Code:
B2
Abstract:
Methods, systems, and kits useful for determining whether a subject is likely to benefit from therapy with an antibody are provided. In particular aspects, cell-bound complement activation products (CB-CAPs) associated with B lymphocytes may serve as diagnostic biomarkers.
Inventors:
Ahern, Joseph, Em.
Ryu, Chow-Chin
Manzi, Susan, M.
Ryu, Chow-Chin
Manzi, Susan, M.
Application Number:
JP2018525527A
Publication Date:
April 01, 2020
Filing Date:
July 29, 2016
Export Citation:
Assignee:
Allegheny Singer Research Institute
International Classes:
G01N33/68; A61P29/00; A61P37/02; A61P37/06; G01N33/53
Domestic Patent References:
| JP2014505264A | ||||
| JP2007537449A |
Foreign References:
| WO2015105973A1 | ||||
| WO2014124098A1 |
Other References:
WILLIAMS, E. M. et al.,Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia,The Journal of Immunology,2006年11月 2日,Vol. 177, No. 10,pp. 7435-7443
Attorney, Agent or Firm:
Maruyama International Patent Office